A Phase 1 Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT125329 in Healthy Subjects, With an Optional Pharmacological Effects Cohort
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Zavacorilant (Primary) ; Prednisone
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 08 Feb 2022 Status changed from recruiting to completed.
- 05 Nov 2021 Planned End Date changed from 30 Sep 2021 to 28 Feb 2022.
- 05 Nov 2021 Planned primary completion date changed from 31 Jul 2021 to 22 Dec 2021.